

# CoC Operative Standard 5.7: Total Mesorectal Excision


December 7, 2020

*Presentation created by CSSP Education Committee*



# Webinar Logistics

- All participants are muted during the webinar
- Questions – including technical issues you may be experiencing – should be submitted through the question pane
- Questions will be answered as time permits
- Please complete the post-webinar evaluation you will receive via email




# Cancer Surgery Standards Program (CSSP)

- The ACS launched the CSSP in June 2020, recognizing growing evidence that adherence to specific operative techniques leads to:

Longer survival



Better surgical outcomes



Improved quality of life





- Shift from standards based in facilities/equipment to **outcomes-based standards**


# Cancer Surgery Standards Program (CSSP)

- Mission: To **improve the quality of care** for persons with cancer
- Goals:
  - **Set evidence-based standards** for the technical conduct of oncologic surgery
  - **Educate surgeons** on the key technical aspects of oncologic procedures
  - **Create tools** which support implementation and adherence to the standards
    - Synoptic operative report templates
    - Integrated documentation in the Electronic Medical Record (EMR)

# Operative Standards for Cancer Surgery



# The CoC Operative Standards (2020)



Standard	Disease Site	Procedure	Documentation
5.3	Breast	Sentinel node biopsy	Operative report
5.4	Breast	Axillary dissection	Operative report
5.5	Melanoma	Wide local excision	Operative report
5.6	Colon	Colectomy (any)	Operative report
5.7	Rectum	Mid/low resection (TME)	Pathology report (CAP)
5.8	Lung	Lung resection (any)	Pathology report (CAP)



# Multidisciplinary panel



James  
Fleshman,  
MD, FACS,  
FASCRS



Patricia Sylla,  
MD, FACS,  
FASCRS



Mariana  
Berho, MD



Anthony  
Villano, MD



Jennie Jones,  
MSHI-HA,  
CHDA, CTR

# CoC Compliance Measures: Standard 5.7


1) TME is performed for patients undergoing radical surgical resection of mid to low rectal tumors

2) TME should result in a **complete or near-complete** total mesorectal excision

3) Pathology reports for resections of rectal adenocarcinoma **document the quality of TME resection** (complete, near-complete, or incomplete) **in synoptic format.**



# Timeline to Achieve Compliance: Standard 5.7




# Complete TME as an Operative Standard

- TME **minimizes** potential operative morbidity
- High quality TME **improves oncologic outcomes**
- TME has been accepted as **standard of care** across multiple societies: ASCRS, NCCN, NAPRC


# TME Improves Oncologic Outcomes

## Lower recurrence



No. at risk	0	6	12	18	24
CRAB trial	269	243	213	193	180
TME trial	661	614	540	428	345

## Prolonged overall survival




No. at risk	0	6	12	18	24
CRAB trial	269	249	237	223	207
TME trial	661	626	558	449	363

Kapiteijn E et al 2002. *J Clin Oncol*.

# Technique Matters: Incomplete TME yields worse oncologic outcomes


Outcome	Complete TME	Incomplete TME	P-value
Overall recurrence (%)	14.9%	28.6%	0.03
Local recurrence (%)	5.5%	11.4%	0.09
Distant recurrence (%)	12.2%	19.2%	0.11
2-year overall survival (%)	90.5%	76.9%	<0.05



Nagtegaal et al 2002. *J Clin Oncol*

# Case Presentation: Mid/Low Rectal Cancer

- 67 year old man with anemia, referred by his PCP after colonoscopy
- Mass found at 8cm from the anal verge → biopsy shows adenocarcinoma, locally advanced but resectable
- Undergoes neoadjuvant chemoradiation → stable disease after restaging
- Referred for low anterior resection with total mesorectal excision (TME)





# Total Mesorectal Excision (TME): Rationale

- Leverages existing tissue planes → promotes safe dissection, avoiding critical neurovascular structures/adjacent organs
- Allows for complete tumor resection and associated draining lymph nodes
- Optimizes the probability for negative margins



# Total Mesorectal Excision (TME): Technique



*Katz et al. 2018, Operative Standards for Cancer Surgery: Volume 2*

© American College of Surgeons 2020—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

[facs.org/cssp](https://facs.org/cssp)

Cancer  
Surgery  
Standards  
PROGRAM  
AMERICAN COLLEGE OF SURGEONS




AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes

100+ years

# Total Mesorectal Excision (TME): Technique

- High ligation of the inferior mesenteric artery (IMA)
- The **posterior mesorectal dissection** lends itself to a readily identifiable, loose areolar tissue plane
- Autonomic nerves coalesce just posterior to this space and are avoided



*Picture courtesy of Dr. Patricia Sylla*

*Katz et al. 2018, Operative Standards for Cancer Surgery: Volume 2*

© American College of Surgeons 2020—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

[facs.org/cssp](https://facs.org/cssp)


Cancer  
Surgery  
Standards  
PROGRAM  
AMERICAN COLLEGE OF SURGEONS



AMERICAN COLLEGE OF SURGEONS  
Inspiring Quality.  
Highest Standards. Better Outcomes.

# Total Mesorectal Excision (TME): Technique

- The **anterior mesorectal dissection** is a tighter space, but when in the correct plane yields a similar areolar dissection
- Care to protect the immediately superficial structures (prostate in men, uterus in women) is critical




*Katz et al. 2018, Operative Standards for Cancer Surgery: Volume 2*



# Total Mesorectal Excision (TME): Technique

- A **complete mesorectal dissection** should yield:
  - Intact mesorectal envelope with smooth border
  - No visible defects >5mm depth
  - No coning effect of the distal specimen
  - No visible muscularis propria



*Katz et al. 2018, Operative Standards for Cancer Surgery: Volume 2*

# CoC Compliance Measures: Standard 5.7


1) TME is performed for patients undergoing radical surgical resection of mid to low rectal tumors

2) TME should result in a **complete or near-complete** total mesorectal excision

3) Pathology reports for resections of rectal adenocarcinoma **document the quality of TME resection** (complete, near-complete, or incomplete) **in synoptic format.**

# How will compliance be assessed?

- TME quality **scored by pathologist** on CAP standardized synoptic report
- Score based on **worst area of specimen**, not the specimen as a whole



## Complete

- Intact bulky mesorectum w/ smooth surface, minor irregularities
- No surface defects >5mm
- No coning towards distal specimen

## Near-complete

- Moderate bulk to mesorectum
- Irregular mesorectal surface, + defects >5mm
- No visible muscularis propria except at insertion of levator muscles

## Incomplete

- Little bulk to mesorectum
- Defects down to muscularis propria
- Circumferential margin w/ irregular borders




# Complete, near complete and incomplete TME




**Complete**  
Optimal quality

- Good bulk of mesorectum, smooth surface, good clearance anteriorly, no defects in mesorectum.



**Near Complete**  
Moderate quality

- Moderate bulk of mesorectum but some irregularity, moderate coning distally may be present.



**Incomplete**  
Poor quality

- Irregular mesorectum with defects more than 1 cm<sup>2</sup> or incision down to the muscularis propria, little bulk of mesorectum, little clearance anteriorly.

Photo courtesy of Dr. Patricia Sylla and Dr. Mariana Berho

# Example of a CAP Rectal Synoptic Report

CAP Approved

Gastrointestinal • Colon and Rectum • Resection • 4.1.0.0

## Macroscopic Evaluation of Mesorectum (required for rectal cancers) (Note C)

- Complete
- Near complete
- Incomplete
- Cannot be determined

## Histologic Type (Note D)

- Adenocarcinoma
  - Mucinous adenocarcinoma
  - Signet-ring cell carcinoma (poorly cohesive carcinoma)
- Medullary carcinoma
- Serrated adenocarcinoma
- Micropapillary carcinoma
- Adenosquamous carcinoma
- Undifferentiated carcinoma
- Carcinoma with sarcomatoid component
- Large cell neuroendocrine carcinoma
- Small cell neuroendocrine carcinoma
- Mixed neuroendocrine-non-neuroendocrine neoplasm (specify components): \_\_\_\_\_
- Other histologic type not listed (specify) \_\_\_\_\_
- Carcinoma, type cannot be determined

## Histologic Grade (Note E)

- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- G4: Undifferentiated
- Other (specify): \_\_\_\_\_
- GX: Cannot be assessed
- Not applicable

## Tumor Extension

- No evidence of primary tumor
- No invasion (high-grade dysplasia)
- Tumor invades lamina propria/muscularis mucosae (intramucosal carcinoma)
- Tumor invades submucosa
- Tumor invades muscularis propria
- Tumor invades through the muscularis propria into pericolorectal tissue
- Tumor invades the visceral peritoneum (including tumor continuous with serosal surface through area of inflammation)
- Tumor directly invades adjacent structures (specify: \_\_\_\_\_)
- Cannot be assessed

## Margins (Note F)

Note: Use this section only if all margins are uninvolved and all margins can be assessed.

- All margins are uninvolved by invasive carcinoma, high grade dysplasia / intramucosal carcinoma, and low grade dysplasia

Margins examined: \_\_\_\_\_  
Note: Margins may include proximal, distal, radial (circumferential) or mesenteric, deep, mucosal, and

- others:
  - + Distance of invasive carcinoma from closest margin (millimeters or centimeters): \_\_\_ mm or \_\_\_ cm
  - + Specify closest margin: \_\_\_\_\_


+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.

## Macroscopic Evaluation of Mesorectum (required for rectal cancers) (Note C)


- Complete
- Near complete
- Incomplete
- Cannot be determined



# Timeline to Achieve Compliance: Standard 5.7




# How Can Programs Optimize Compliance?



Ensure institution is utilizing **standardized CAP reports** for all rectal cancer procedures



**Document** performance of TME and indication (low-mid rectal tumor) **clearly** in operative notes



**Encourage communication** amongst surgeons, pathologists, & registrars



# Panel discussion



James  
Fleshman,  
MD, FACS,  
FASCRS



Patricia Sylla,  
MD, FACS,  
FASCRS



Mariana  
Berho, MD



Anthony  
Villano, MD



Jennie Jones,  
MSHI-HA,  
CHDA, CTR

## Standard 5.7: Total Mesorectal Excision

# Summary


### Operation

Total mesorectal excision (TME) is performed for mid and low rectal tumors, resulting in **complete** or **near-complete** TME

Keep fascia propria of rectum intact, operate in plane between rectum and presacral fascia

- Ensures negative margins
- Protects neurovascular structures

### Maintain the 'Holy Plane'



### Pathology Documentation

Quality of TME documented in synoptic report:

- Complete
- Near-Complete
- Incomplete

### When?

2021:  
**Implementation**

2022 site visits:  
**70% Compliance**



# Special thanks

## **Moderator:**

James Fleshman, MD, FACS, FASCRS

## **Panelists:**

Mariana Berho, MD

Jennie Jones, MSHI-HA, CHDA, CTR

Patricia Sylla, MD, FACS, FASCRS

Anthony M. Villano, MD

## **CSSP Leadership & Staff:**

CSSP Chair: Matthew H.G. Katz, MD FACS

CSSP Vice-Chair: Kelly K. Hunt, MD, FACS

CSSP Senior Manager: Amanda Francescatti, MS

CSSP Program Coordinator: Linda Zheng

## **CoC Leadership:**

CoC Chair: Timothy W. Mullett, MD, FACS

## **NAPRC**

## **CSSP Education Committee**

## **ACS Cancer Programs Staff:**

Asa Carter: Senior Manager, Education & Training

Chantel Ellis: Administrator, Education & Training

Andrea Scrementi: Meetings and Events Administrator

**Questions?** [cssp@facs.org](mailto:cssp@facs.org)

## Resources

**ACS Cancer Surgery Standards Program (CSSP)**

[www.facs.org/cssp](http://www.facs.org/cssp)

**National Accreditation Program for Rectal Cancer (NAPRC)**

<https://www.facs.org/quality-programs/cancer/naprc>

**College of American Pathologists (CAP) protocol**

[www.cap.org](http://www.cap.org)

**Rectal Cancer Synoptic Operative Report**

*available in Appendix of NAPRC 2020 Standards*

# References

- 1) Chang G, Cleary RK, Dietz E, et al. 2018. Chapter 4: Proctectomy. In Hunt KH, Katz MH, Veeramachaneni, et al. *Operative Standards for Cancer Surgery: Volume 2* (190-205). Philadelphia, PA: Wolters Kluwer.
- 2) Kapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. *Br J Surg*. 2002 Sep;89(9):1142-9.
- 3) Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH; Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. *J Clin Oncol*. 2002 Apr 1;20(7):1729-34.
- 4) Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, Rafferty J; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of rectal cancer (revised). *Dis Colon Rectum*. 2013 May;56(5):535-50.